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Mesoporous bioactive glasses equipped with stimuli-responsive 
molecular gates for the controlled delivery of levofloxacin against 
bacteria 
Lorena Polo,[a,b] Natividad Gómez-Cerezo,[c,b] Alba García-Fernández,[a,c,d] Elena Aznar,[a,b,d] José-Luis 
Vivancos,[a,b,d,e] Daniel Arcos,[c,b] María Vallet-Regí,[c,b] and Ramón Martínez-Máñez*[a,b,d,e]    
 
Abstract: Increase of bone diseases incidence has boosted the 
study of ceramic biomaterials as a potential osteo-inductive scaffolds. 
Particularly, mesoporous bioactive glasses have demonstrated to 
possess a broad application in the bone regeneration field, due their 
osteo-regenerative capability and their ability to release drugs from 
its mesoporous structure. These special features have been studied 
as an option to fight against bone infection, which is one of the most 
common problems regarding bone regeneration therapies. In this 
work, we develop a mesoporous bioglass functionalized with 
polyamines and capped with ATP as molecular gate for the 
controlled release of the antibiotic levofloxacin. Phosphate bonds of 
the ATP are hydrolyzed in the presence of acid phosphatase 
(APase), which significantly increases its concentration in bone 
infection due to the activation of bone resorption processes. The 
solid has been characterized and tested successfully against 
bacteria. The final gated solid only induces bacterial death in the 
presence of acid phosphatase. Additionally, it has also been 
demonstrated that the solid is not toxic for human cells. The double 
function of the prepared nanodevice as drug delivery system and 
bone regeneration enhancer, confirms the possible development of a 
new approach in tissue engineering field, where controlled release of 
therapeutic agents can be finely tuned at the same time that 
osteoinduction is favoured. 
Introduction 
Bone diseases have gained importance over the last years 
due to the ageing of population. Incidence of illnesses like 
osteoporosis, bone tumours and bone fractures is 
remarkably higher in elderly patients, due to age-related 
loss and weakening of bone tissue.[1] Treatment of these 
kind of diseases usually implies the use of implants and 
bone prosthesis; however, surgical procedures are not 
always infallible, since they can result in other medical 
complications.[2,3] Currently, bacterial infection is one of the 
most frequent problems related to implant surgery.[4] The 
creation of a bacterial biofilms on the surface of the implant 
requires many times its removal and leads to healing 
difficulties, lowering the life-quality of patients.[5] Therefore, 
the need of new therapies and devices for the treatment of 
these diseases has led to arise the development of 
innovative biomaterials for bone tissue engineering.[6,7] 
Among them, mesoporous bioactive glasses are promising 
and innovative silica-based bioceramics which have a 
meaningful significance in bone tissue engineering field 
due to their excellent properties.[8–10] These materials are 
biocompatible and resorbable, and are able to integrate 
living bone in a physiological environment through  the 
formation of hydroxyapatite on the surface of the 
implant.[11,12] This apatite-like phase is very similar to the 
inorganic component of the bones, and its enhanced 
formation in bone defects greatly favours bone 
regeneration.[13] These features make mesoporous 
bioactive glasses ideal materials for bone grafting and bone 
regeneration therapies. Apart from that, their mesoporous 
structure gives them special surface features,[14] and 
converts them suitable for drug delivery of certain 
substances.[15,16]  
 
Several studies have reported the storage and release of 
different therapeutic drugs in order to treat local bone 
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pathologies.[17] However, these examples are in most cases 
based on sustained release processes which are not able 
to avoid unspecific release. Taking into account these 
precedents, it is of interest the development of more 
sophisticated systems able to promote bone regeneration 
and achieve controlled drug delivery only in specific 
scenarios. Various nanostructured systems have been 
recently designed for the controlled release of anticancer 
and antiviral drugs.[18,19] Moreover, the preparation of new 
drug nanocarriers able to respond to external stimuli to 
perform a controlled and local cargo release has been of 
enormous importance in the field of biomedicine.[20,21] In this 
context, one appealing approach to succeed in this goal is 
the incorporation of molecular gates to mesoporous 
bioglasses. A molecular gate is a molecular or 
supramolecular-based system able to control mass 
transport and respond to specific external stimuli which can 
be implemented in a porous scaffold.[22,23] Different gated 
materials using molecules, biomolecules or supramolecules 
have been described. In these examples, the gating 
mechanism can be switched between a “closed” to “open” 
state, or vice versa, by the application of a selected 
stimulus as light,[24] temperature,[25,26] magnetic fields,[27] 
ultrasounds,[28] pH changes,[29] redox reactions[30] or 
biomolecules as enzymes.[31-24] Molecular gates have been 
widely studied and incorporated in mesoporous silica 
supports,[35] but very rarely have been implemented in 
mesoporous bioglasses.[36] Despite the relevance of 
combining the osteoinductive features of mesoporous 
bioactive glasses and controlled release characteristics of 
molecular gates, much effort in the development of this kind 
of functional biomaterials should still be accomplished and 
applied to a relevant context. In this scenario, the aim of 
this work is the development of a gated system able to 
respond specifically to the presence of a stimulus related 
with bone infection.  
 
For this purpose, an 80%SiO2-15%CaO-5%P2O5 (% mol) 
mesoporous bioglass was selected as inorganic support 
(S1). This solid was loaded with levofloxacin, which is a 
wide range antibiotic, and functionalized with 3-[2-(2-
aminoethylamino)ethylamino]propyl-trimethoxysilane. The 
resulting solid (S2) was treated with ATP (Adenosine 5′-
triphosphate disodium salt hydrate) and EDC, in order to 
covalently attach the phosphate group in ATP with the 
amine in N3 (solid S3). In this way, ATP molecules were 
grafted to the surface of the solid, blocking the entrance to 
the mesopores and keeping the cargo in the pore voids. In 
a non-pathological scenario, ATP molecules would remain 
intact, and levofloxacin would continue stored inside the 
pores of the mesoporous bioactive glasses. However, in the 
presence of a stimulus as acid phosphatase (APase), ATP 
molecules would be hydrolysed, unblocking the surface of 
the pores and allowing the release of the drug. This 
mechanism has been previously used by the present 
authors to develop gated 3D scaffolds and as intracellular 
drug delivery system.[37,35] APase was selected as stimulus 
since its concentration significantly increases with 
osteoclast activity.[38,39] Both osteoblast deposition and 
osteoclast resorption are two balanced processes which are 
fundamental for bone regeneration.[40] However, the 
presence of infectious microorganisms as Staphylococcus 
aureus can enhance osteoclast resorption and lead into 
bone damage with the subsequent increase of acid 
phosphatase levels.[41] The action mechanism of 
phosphatase enzymes consists of the cleavage of 
phosphate bonds. Thus, in a bone infection scenario ATP 
molecules would be cleaved, unblocking the entrance to the 
mesopores of the MBG and allowing the release of the drug 
to the media (Scheme 1).  
 
Scheme 1. Schematic representation of solid S3 capped with the ATP 
molecular gates. 
 
 
The resulting solid (S3) was characterized, to assure that 
the functionalization process did not modify the properties 
of the support. Controlled release tests were carried out 
both in the presence and the absence of acid phosphatase, 
achieving drug release only in the presence of the stimulus. 
Bioactivity assays were carried out with gated and non-
gated solids, to demonstrate that the molecular gates do 
not slow down bioactive processes. Moreover, bacterial 
death experiments were carried out in order to confirm the 
antibacterial activity of the solid in a specific scenario. 
Finally, cytotoxicity assays were carried out with the gated 
solid to assess that the solid is not toxic for human cells. 
Results and Discussion 
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The aim of this work was the development of a gated 
bioglas able to deliver an antibiotic (levofloxacin) in the 
presence of a stimulus (presence of APase) related with 
bone infection. For this, a mesoporous bioactive glass (solid 
S1) was loaded with levofloxacin and then functionalized 
first with N3 and then with ATP to yield solids S2 and S3, 
respectively. The synthesized solids were correspondingly 
characterized in order to confirm the presence of the ATP 
gates, and to demonstrate that the mesoporous properties 
of the final solid S3 had not been damaged upon the 
functionalization and capping processes. Thus, chemical, 
structural and textural characterization was carried out in 
solids S1, S2 and S3. The highly ordered mesoporous 
structure of the solids was confirmed by powder X-ray 
diffraction (XRD). XRD pattern for S1 (Figure 1) shows a 
single peak at 1.71 ° that corresponds to a (10) Bragg 
reflection of a 2D hexagonal p6m structure. S2 and S3 
show similar peaks. Peaks intensity decreases after the 
loading and capping process, pointing out the introduction 
of certain degree of disorder with these processes. 
 
Figure 1. Powder X-ray diffraction patterns of solids S1, S2 and S3. 
 
Transmission electron microscopy studies were also carried 
out in order to confirm XRD results. TEM image of S1 
evidences mesoporous structure, showing alternate black 
and white stripes typical of p6m hexagonal pore symmetry 
(Figure 2). TEM images of S2 and S3 show that 
mesoporous structure of the solids was not affected during 
the loading, functionalization and capping processes.  
 
Textural properties of the prepared materials were 
characterized by N2 adsorption-desorption studies. The N2 
adsorption-desorption isotherm of S1 shows a curve of type 
IV, typical of mesoporous solids (Figure 3). The curve 
shows an adsorption step between P/P0 0.4 and 0.6, due to 
N2 condensation inside pores. Moreover, the curve has a 
H1 hysteresis loop also typical of mesoporous materials, 
which indicates that mesopores have open cylinder 
morphology. N2 adsorption-desorption isotherm of S3 
shows a decrease of BET surface and specific pore volume 
when compared with S1, due to the loading of the pores  
 
 
Figure 2. Transmission electron microscope images of solids S1, S2 
and S3. 
 
and grafting of ATP. The hysteresis loop of the curve for S3 
changes to type H2 when compared with that of S1, which 
means that the morphology of the pore has also changed, 
indicating an ink-bottle shape according to the capping of 
the material. Finally, pore size distribution was determined 
from the adsorption branch of the isotherm by means of the 
Barret-Joyner-Halenda (BJH) method and the surface area 
was determined using the Brunauer-Emmett-Teller (BET) 
method. Textural parameters values of S1 and S3 are 
summarized in Table 1.  
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Figure 3. N2 adsorption-desorption isotherms for solids S1 and S3. 
 
Moreover, thermogravimetric analysis was performed in 
solid S3 to determine the amount of N3 and ATP attached 
to the surface of the material. Results are shown in Table 2. 
Moreover, the amount of levofloxacin contained into the 
pores was determined. For this, 10 mg of solid S3 were 
treated with APase and the solid allowed to release the 
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cargo for 24 hours. From a fluorescence calibration curve, it 
was determined that the amount of levofloxacin was 2.53 
mg per gram of S3. 
 
Table 1. Textural parameters of solids S1 and S3. 
Solid BET surface 
(m2·g-1) 
Pore Volume 
(cm3·g-1) 
Pore size (nm) 
S1 305.50 0.386 5.5 
S3 233.98 0.210 3.9 
 
 
Table 2. Organic content (α, mg/g of solid) in solid S3. 
Solid αlevo  αN3 αATP 
S3 2.53 179.8 22.97 
 
 
As previously stated, the designed nanodevice is based on 
the combination of a biocompatible material and a gating 
mechanism to induce apatite-like formation and control drug 
release at the same time. For this reason, both bioactivity 
and drug delivery assays were carried out with solid S3. In 
order to demonstrate that the ATP-capped solid is capable 
to release the payload only in specific scenarios, drug 
delivery studies were undertaken in the presence and the 
absence of acid phosphatase. In a typical experiment, 2 mg 
of S3 were suspended in water at pH 7.6 and stirred for 24 
hours in the presence and the absence of the stimulus. At 
given time intervals, fractions of both suspensions were 
taken and filtrated to remove the solid. Then, drug released 
from the pore voids was monitored by fluorescence 
spectroscopy (λex 292 nm, λem 494 nm). Drug delivery 
kinetics is shown in Figure 4. In the absence of stimulus, 
the solid showed poor release, (less than 20 % of the 
maximum cargo delivered). Contrarily, in the presence of 
acid phosphatase, a remarkable payload of the drug was 
achieved, reaching maximum delivery at 24 hours. These 
results are consistent with the design of the nanodevice. In 
the absence of APase, the ATP gates remain closed, 
blocking the entrance to the pores and avoiding levofloxacin 
leakage. When acid phosphatase is added the phosphate 
bonds in ATP are hydrolysed, pore entrances are 
unblocked and levofloxacin is released.  
 
In order to demonstrate that gate opening was caused by 
the presence of APase, controlled release experiments 
were carried out in the presence of other enzymes as 
amylase and lipase. Delivery kinetics of this experiment are 
shown in Figure 4 and demonstrate that the presence of 
other enzymes did not induce cargo delivery.  
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Figure 4. Delivery kinetics of solid S3 in the presence of acid 
phosphatase (a), amylase (b) and lipase (c), and in the absence of acid 
phosphatase (d).  
 
Additionally, levofloxacin kinetics release can be explained 
by using the Higuchi model.[42,43] This simple model, used 
for similar systems,[44] predicts that the release of the cargo 
will be dependent on the square root of time when delivery 
is based on a Fickian diffusion process. In this case, the 
amount of guest release, Qt, per unit of exposed area at 
time t can be described by the equation: 
 
Qt = kH t1/2  
 
where kH is the release rate constant for the Higuchi model. 
When applied to the experimental data, a good linear fitting 
was observed (see Figure 5) and a value of KH of 35,836 
was calculated. These data suggest that the delivery of 
levofloxacin from pores of solid S3 is basically a diffusive 
process.  
 
Figure 5. Delivery kinetics of solid S3 versus the square root of time 
 
Molecular gates provide to mesoporous bioactive glass the 
ability to perform controlled drug release, but also imply a 
certain modification of the bioactive glass surface. 
Therefore, we found important to check that the molecular 
gates did not harm the bioactive capability of the material. 
Thus, the bioactive behaviour of solid S3 was studied by 
soaking the material in simulated body fluid (SBF) at 37 °C. 
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As solid S3 was meant to be bioactive in the presence of 
acid phosphatase, the bioactivity test with S3 was carried 
on in the absence and the presence of the enzyme in order 
to study the system with both, open and closed gates. 
Bioactivity of solids was studied by FTIR spectroscopy to 
identify the signals corresponding to the presence of 
phosphate bonds. In addition, field emission scanning 
microscopy images were taken with the purpose of 
confirming FTIR results, and EDX analysis was performed 
in order to study the components of the solids surface 
before and after soaking in SBF. FTIR spectra of S3 in the 
presence and the absence of APase at 0 and 72 hours are 
shown in Figure 6. Non-soaked solid S3 shows typical Si-O 
signal at 900-1250 cm-1, and signal in 520-610 cm-1 
corresponding to the presence of amorphous phosphate 
bonds. Moreover, amine δ(C-N) and δ(C-H) bands are 
observed at 1470 cm-1 and 1650 cm-1. A typical weak 
amine δ(N-H) band is also observed at 3250 cm-1. The 
FTIR spectrum of S3 after being soaked for 72 hours in the 
absence of APase remains unchanged. FTIR spectra of 
solid S3 in the presence of acid phosphatase shows typical 
MBG signals and amine signals at 1470, 1650 and 3300 
cm-1, but a splitting of the signal at 560 and 600 cm-1 is also 
clearly observed after 24 and 72 hours of soaking. This 
splitting demonstrates the presence of P-O bonds 
corresponding to a crystalline phase, which is consistent 
with the formation of apatite.  
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Figure 6. FTIR spectra of non-soaked S3, 72 hours soaked S3 with no 
APase, and 72 hours soaked S3 with APase.   
 
In order to confirm the results given by FTIR spectroscopy, 
FESEM images of the different treated solids were taken, 
and EDX analysis was performed. Si, Ca and P 
percentages are shown in Table 3. Non-soaked solid S3 
showed a neat surface with no apatite (Figure 7A), and S3 
soaked for 72 hours in the absence of APase also presents 
the same neat surface, with low calcium and phosphor 
percentages (Figure 7B). Actually, for the later the amount 
of calcium decreases due to the release of Ca2+ ions from 
the mesoporous bioglass. Ca2+ release from the material 
also causes the rise of silicon percentage, while 
phosphorous amount slightly rises too. These results are  
 
 
Figure 7. SEM images of non-soaked S3 (A), 72 hours soaked S3 with 
no APase (B), and 72 hours soaked S3 with APase (C).   
 
consistent with FTIR spectra, which show no crystalline P-O 
presence in S3 containing the ATP molecular gates. 
However, when S3 is soaked for 72 hours in the presence 
of acid phosphatase, a new thick phase is rapidly formed on 
the surface of the solid (Figure 7C). EDX analysis confirms 
the high amounts of calcium and phosphorous. Ratio Ca/P 
was found to be 1.46, which is in agreement with the 
presence of the apatite-like phase. These results are also 
consistent with FTIR spectra, demonstrating that the solid 
with “open gates” recovers its bioactive properties.  
 
Table 3. EDX results of Si, Ca and P percentages in non-soaked S3, 72 
hours soaked S3 with no APase, and 72 hours soaked S3 with APase.   
% S3 0h S3 72h S3-APase 72h 
Si 85.37 90.03 75.66 
Ca 11.13 6.01 14.46 
P 3.50 3.96 9.88 
 
The loss of bioactivity after the incorporation of the ATP 
molecular gates has not been deeply studied in this work. A 
hypothetical explanation to the non-bioactive behaviour of 
solid S3 in the absence of acid phosphatase could be 
related to the ability of mesoporous bioglasses to release 
Ca2+ ions to the media. As stated in literature,[45] bioactive 
processes start with the Ca2+ leaking from the silica net and 
undergoing an exchange with H+ ions. In a physiological 
media, calcium ions are capable of reacting with 
phosphates to form a crystalline apatite layer. It has also 
been reported that phosphate groups have a high affinity for 
Ca2+ ions.[45] In this context, it is possible that the phosphate 
net formed by the ATP molecules could entrap Ca2+ ions, 
avoiding the leakage to the media and therefore inhibiting 
bioactive behaviour. Moreover, the breaking of the 
phosphate net would allow the entrapped calcium release, 
which is consistent with results of S3 in the presence of 
acid phosphatase. Actually, the release of ATP molecules 
would rise phosphates concentration in the media, which 
could also favour the apatite phase formation.  
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Thus, solid S3 was not bioactive when capped with ATP. 
However, once mimicked bacterial infection conditions (with 
the subsequent increase of acid phosphatase in the media), 
the S3 bioactivity was restored.  
 
As solid S3 was expected to release an antibiotic drug in 
the presence of an infection, bacterial viability assays were 
carried out with the purpose of demonstrating the 
bactericide effect of the nanomaterial. In a typical 
experiment S3 was stirred at 37 °C in the absence and the 
presence of acid phosphatase for 24 hours. Then, two 
different E.coli suspensions were treated with 50 µL of each 
sample. Bacteria were stirred for 20 minutes and afterwards 
100 µL of each suspension was seeded in an agar plate 
and incubated at 37 °C. After 24 hours, cell viability was 
quantified by counting the colonies. As seen in Figure 8, 
bacteria treated with the S3 suspension (without APase) 
showed a viability of 80.41 %, which is remarkably higher 
than 18.75 % of viability when bacteria were treated with 
the S3 suspension previously treated with APase. 
Decreased viability for the former compared with control 
(100 %) can be due to the residual release of levofloxacin in 
the absence of acid phosphatase. Moreover, bacteria were 
also treated with a solution containing only APase and no 
significant bacterial death was observed, demonstrating 
that the bacterial death was due to the presence of 
released levofloxacin (data not shown). These results are 
consistent with the design of the gated support S3. In the 
presence of acid phosphatase, the gated support delivers 
levofloxacin in a much higher amount that that in the 
absence of the stimulus. The higher concentration of drug 
in APase supernatant undertakes higher cell toxicity, 
demonstrating that the bactericide effect of the solid is only 
achievable in the presence of an infection marker as acid 
phosphatase.  
 
 
Figure 8. Bacterial viability of E.coli when treated with 50 and 100 μL of 
a suspension of S3 in the presence and the absence of APase. 
 
Finally, cytotoxicity studies were carried out in order to 
demonstrate that the prepared material is compatible with 
human cells. For this purpose, U-2 OS human 
osteosarcoma cells were treated with different amounts (25, 
50, 100 and 200 μg·mL-1) of S3 for 24 and 48 hours, and 
mitochondrial activity (WST-1 assays) was measured after 
these intervals. As seen in Figure 9, S3 solid was well-
tolerated by U-2 OS cells at concentrations up to 200 
µg·mL-1 after 24 and 48 hours of exposure, which means 
that the prepared solid is not toxic. Thus, it was 
demonstrated that the ATP-gated mesoporous bioactive 
glass is biocompatible, and is a good strategy to treat bone 
infection and improve bone regeneration without causing 
any damage to human cells. 
 
Figure 9. Cell viability of U-2 OS cells in the presence of S3 (0, 25, 50, 
100 and 200 µg·mL-1) after 24 hours (black) and 48 hours (gray) of 
incubation. Three independent experiments containing triplicates were 
carried out. Data are expressed as mean ± s.e. 
Conclusions 
In summary, we have developed a double-strategy device 
which is able to enhance bone regeneration and achieve 
controlled drug release against bacteria. A mesoporous 
bioactive glass was loaded with levofloxacin, functionalized 
with a polyamine, and capped with ATP molecules. The 
structure of the resulting solids was characterized by 
standard techniques, demonstrating that the incorporation 
of molecular gates into MBG did not imply any changes in 
its textural properties. Then, both drug release capability 
and bioactive behaviour were tested. Drug release 
experiments were carried out with the final solid in the 
presence and the absence of acid phosphatase, and also in 
the presence of other enzymes as amylase and lipase, 
observing only a complete release of the drug when acid 
phosphatase was present. This demonstrates that 
controlled release is achieved only in the presence of a 
specific stimulus typical of a bone infection environment. On 
the other hand, bioactivity studies were carried out with S3 
in the presence and the absence of acid phosphatase. Our 
studies proved that the solid did not have bioactive 
capabilities when capped with ATP gates, however, it was 
found that the solid recovered its bioactive behaviour in the 
presence of the acid phosphatase stimulus. Antibacterial 
effect of S3 was also studied, and it was demonstrated that 
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solid treated with acid phosphatase was much more 
effective killing bacteria than the untreated solid. Finally, 
cytotoxicity studies were carried out with S3, showing that 
the prepared material was not toxic for U-2 OS human cells 
upon 24 and 48 hours. In this way, our double-strategy 
design has been proved to be successful as a drug delivery 
system and bone regeneration enhancer. The present work 
confirms the versatility of the used gating mechanism 
previously applied to the development of 3D scaffolds and 
as intracellular drug delivery system. This kind of double-
edged nanodispositives opens up a new approach in tissue 
engineering field, particularly in the treatment of osseous 
diseases as bone infection. 
Experimental Section 
Chemicals 
Chemicals poly(ethylene glycol)-block-poly(propylene glycol)-block-
poly(ethylene glycol) (P123), tetraethyl orthosilicate (TEOS), triethyl 
phosphate (TEP), calcium nitrate  Ca(NO3)2·4H2O, 3-[2-(2-
aminoethylamino)ethylamino]propyl-trimethoxysilane (N3), adenosine 5’-
triphosphate disodium salt hydrate (ATP), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC), acid phosphatase, acetonitrile 
anhydrous, hydrochloric acid, levofloxacin, Dulbecco's Modified Eagle's 
Medium (DMEM), fetal bovine serum (FBS) and Dulbecco’s phosphate-
buffered saline (PBS) were purchased from Sigma–Aldrich Química S.A. 
LB medium was provided from Laboratorios Conda. Cell proliferation 
reagent WST-1 was obtained from Roche Applied Science.  
 
General Techniques 
FTIR spectroscopy was carried out with a Tensor 27 FT-IR spectrometer 
(Bruker). TEM images were obtained with a 100 kV Jeol JEM-1010 
microscope. FESEM images were obtained with a ZEISS ULTRA 55. 
Powder X-ray diffraction measurements were performed on a Philips D8 
Advance diffractometer using Cu Kα radiation. Textural properties of the 
calcined materials were determined by nitrogen adsorption porosimetry 
by using a Micromeritics TriStar II PLUS porosimeter. To perform the N2 
adsorption measurements, the samples were previously degassed under 
vacuum for 24 hours, at 90 °C. Surface area was determined using the 
Brunauer-Emmett-Teller (BET) method.[46] Pore size distribution between 
0.5 and 40 nm was determined from the adsorption branch of the 
isotherm by means of the Barret-Joyner-Halenda (BJH) method.[47] For 
cell proliferation test, cell viability measurements were taken in a Wallac 
1420 workstation. Thermogravimetric analysis were carried out on a 
TGA/SDTA 851e Mettler Toledo balance, using an oxidant atmosphere 
(air, 80 mL/min) with a heating program consisting on a heating ramp of 
10 ⁰C per minute from 393 to 1273 K and an isothermal heating step at 
this temperature during 30 minutes. 
 
Synthesis of materials  
Synthesis of mesoporous bioactive glass (S1). 80%SiO2-15%CaO-
5%P2O5 (% mol) mesoporous glass (S1) was synthetized by evaporation 
induced self-assembly (EISA) method, using P123 triblock copolymer as 
structure directing agent. TEOS, TEP and calcium nitrate 
Ca(NO3)2·4H2O were used as SiO2, P2O5 and CaO sources respectively. 
In a typical synthesis, 4 g of P123 were dissolved in 60 g of ethanol with 
1 mL of HCl 0.5 M solution at room temperature. Afterwards, 7.18 mL of 
TEOS, 0.73 mL of TEP and 1.29 g of Ca(NO3)2·4H2O were added under 
stirring in 3 hours intervals. The resulting solution was stirred for 12 
hours and casted into Petri dishes (9 cm in diameter). The colourless 
solution was evaporated at 37 °C for 1 day. Eventually, the dried gels 
were removed as homogeneous and transparent membranes and 
heated at 700 °C for 3 hours under air atmosphere. Finally, the MBG 
powder was gently milled and sieved, collecting the particle size fraction 
below 20 µm. 
 
Synthesis of S2. 500 mg of S1 were suspended in a solution of 145 mg 
of levofloxacin in 20 mL of anhydrous acetonitrile under inert 
atmosphere. After stirring for 24 hours in order to achieve the maximum 
pore loading, 0.5 mL of 3-[2-(2 aminoethylamino)ethylamino] propyl-
trimethoxysilane (N3) was added, and the mixture was stirred for 5.5 
hours. Finally, the solid was filtered and dried under vacuum.  Following 
this procedure, the levofloxacin spectrum does not change before and 
after loading into the mesoporous bioglass. 
 
Synthesis of S3. 400 mg of solid S2 were suspended in a solution 
containing EDC 0.6 M, ATP 0.5 M and an excess of levofloxacin. The pH 
of the solution was previously adjusted to 7.6 with NaOH. The 
suspension was stirred for 6 hours at room temperature. The resulting 
solid was filtered and dried under vacuum.  
 
Stimuli-responsive studies with S3 
4 mg of S3 were suspended in 10 mL of water at pH 7.6 adjusted with 
NaOH. The suspension was divided in two, and acid phosphatase (2.5 
mg, 1.25 enzymatic units) was added to one of the samples. Both 
samples were stirred at 400 rpm and 37 °C, and then several 250 µL 
aliquots were taken for each sample at different times (0, 1, 2, 4, 7 and 
24 hours). These aliquots were filtered with PTFE filters (0.22 µm) to 
monitor the levofloxacin release by fluorescence spectroscopy (λex 292 
nm, λem 494 nm). Moreover, the same experiment was performed in the 
presence of other enzymes as amylase and lipase, and in the presence 
of denatured APase. For this, 10 mg of S3 were suspended in 25 mL of 
water at pH 7.6 and the suspension was divided in five samples. APase, 
denatured APase, lipase and amylase (7.5 enzymatic units) were added 
to respective samples. The samples were stirred at 400 rpm and 37 °C, 
and then 250 µL aliquots were taken for each sample at different times. 
These aliquots were filtered with PTFE filters (0.22 µm) to monitor the 
levofloxacin release by fluorescence spectroscopy (λex 292 nm, λem 494 
nm). 
 
Bioactivity assays with S1 and S3.  
In vitro bioactivity assays were carried out on S1 and S3 solids. 10 mg of 
each solid were soaked into 2 mL of filtered simulated body fluid (SBF)35 
at 37 °C under sterile conditions. The evolution of the solids surfaces 
were analysed by Fourier transform infrared (FTIR) spectroscopy and 
field emission scanning electron microscopy (FESEM). 
 
Bacterial viability assay 
E. coli DH5α culture conditions. For bacterial viability studies, 
Escherichia coli (E.coli) DH5α cell culture was used. Bacteria cells were 
maintained in glycerol 15 % at -80 °C. For the assays, cells were grown 
for 24 hours at 37 °C and under constant stirring with 5 mL of LB 
medium. Cells from 1 mL of culture were collected by centrifugation for 
30 seconds at 13000 rpm and resuspended in 1 mL of milliQ water at pH 
7.6.  
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Bacterial viability assay. In order to determine the antibacterial effect 
of S3, 5 mg of the solid were stirred in water at pH 7.6 in the absence 
and the presence of acid phosphatase for 24 hours. Then, two 
suspensions of 104 cells·mL-1 were prepared and treated with 50 µL of 
each sample. A control experiment with no solid was also carried out. 
The suspensions were stirred at 180 rpm (37 °C) during 10 minutes. 
Then, they were suitably diluted with milliQ water (pH 7.6) in order to 
obtain a cell growth easy to quantify. Finally, 100 µL of the new dilutions 
were seeded in LB plates (3 % agar) and incubated at 37 °C for 24 
hours. Then, Colony Formation Units (CFU) were quantified. 
 
Citotoxicity assay  
Cell culture conditions 
U-2-OS human osteosarcoma cells were purchased from ATCC and 
were grown in DMEM supplemented with 10 % of FBS. Cells were 
incubated at 37 °C in an atmosphere of 5 % carbon dioxide and 95 % air 
and underwent passage twice a week.  
 
Cell toxicity assay. In order to study viability of cells in contact with S3, 
U-2-OS cells were seeded in a 96-well plate in a density of 10.000 
cells·well-1 and treated with 25, 50, 100 and 200 μg·mL-1 of S3 in PBS. A 
control assay with no solid was also carried out. After 24 and 48 hours of 
incubation, WST-1 was added in order to determine cell viability. Cells 
were incubated for 60 minutes, and then absorbance was measured at 
595 nm.  
 
Statistics 
Statistics Data are expressed as means-standard deviations of 
experiments. Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) version 22 software (IBM). 
Statistical comparisons were made by analysis of variance (ANOVA). In 
all of the statistical evaluations, P<0.01 was considered as statistically 
significant. 
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